Moderna's stock soars 10% to lead S&P 500 gainers as Oppenheimer upgrades to buy

Moderna Inc.’s stock soared 10% Tuesday to lead S&P 500 index gainers, after Oppenheimer upgraded the stock to the equivalent of buy and said it expects the biotech to have five products approved by 2026.Analysts led by Hartaj Singh upgraded the stock MRNA, +11.61% to outperform from perform and said it expects it to perform better this year than the dismal showing recorded in 2023. The company currently has just one approved product, its mRNA-based COVID-19 vaccine, which has already passed peak sales. Bu ...